Shares of Phio Pharmaceuticals Corp. (PHIO) nearly quadrupled on Monday after the biotech firm announced promising results from its Phase 1b trial for the cancer immunotherapy PH-762, designed to ...

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company advancing its INTASYL ® gene silencing technology focused on immuno-oncology therapeutics.

Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL ® gene silencing technology to treat cancer. Robert Infarinato ...

--Phio Pharmaceuticals Corp., a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor ...

Phio announced today that it has fulfilled the required enrollment for safety in its third dose cohort in its Phase 1b dose escalating clinical study for their lead compound PH-762.

Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Phio Pharmaceuticals Corp:Phio Pharmaceuticals - Pricing Of Public Offering Of 2 Million Units At Public Offering Price Of $4.00 Per Unit ...

On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro ...

Phio announced today a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds.